All In Biotech

Drug Trial Radar · NCT05121324

Pediatric Dose Optimization for Seizures in Emergency Medical Services

Pediatric Dose Optimization for Seizures in EMS (PediDOSE)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,897 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,897

Actual

Start

Aug 8, 2022

Primary completion

Jul 31, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS); University of Utah; Baylor College of Medicine
First posted
Nov 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Pediatric Dose Optimization for Seizures in Emergency Medical Services (PediDOSE) study is designed to improve how paramedics treat seizures in children on ambulances. Seizures are one of the most common reasons why people call an ambulance for a child, and paramedics typically administer midazolam to stop the seizure. One-third of children with active seizures on ambulances arrive at emergency departments still seizing. Prior research suggests that seizures on ambulances continue due to under-dosing and delayed delivery of medication. Under-dosing happens when calculation errors occur, and delayed medication delivery occurs due to the time required for dose calculation and placement of an intravenous line to give the medication. Seizures stop quickly when standardized medication doses are given as a muscular injection or a nasal spray. This research has primarily been done in adults, and evidence is needed to determine if this is effective and safe in children. PediDOSE optimizes how paramedics choose the midazolam dose by eliminating calculations and making the dose age-based. This study involves changing the seizure treatment protocols for ambulance services in 20 different cities, in a staggered and randomly-assigned manner. One aim of PediDOSE is to determine if using age to select one of four standardized doses of midazolam and giving it as a muscular injection or nasal spray is more effective than the current calculation-based method, as measured by the number of children arriving at emergency departments still seizing. The investigators believe that a standardized seizure protocol with age-based doses is more effective than current practice. Another aim of PediDOSE is to determine if a standardized seizure protocol with age-based doses is just as safe as current practice, since either ongoing seizures or receiving too much midazolam can interfere with breathing. The investigators believe that a standardized seizure protocol with age-based doses is just as safe as current practice, since the seizures may stop faster and these doses are safely used in children in other healthcare settings. If this study demonstrates that standardized, age-based midazolam dosing is equally safe and more effective in comparison to current practice, the potential impact of this study is a shift in the treatment of pediatric seizures that can be easily implemented in ambulance services across the United States and in other parts of the world.

Conditions

  • Seizures

Interventions

  • Standardized seizure protocolDrug

    The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).

  • Conventional seizure protocolDrug

    The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal. for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seizing on emergency department arrivalTime frame: Between arrival to the emergency department and 10 minutes after arrival

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

  • Children's Hospital of Los Angeles

    Los Angeles, California

  • University of California, Davis

    Sacramento, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Children's National Hospital

    Washington D.C., District of Columbia

  • Emory University

    Atlanta, Georgia

  • Indiana University

    Indianapolis, Indiana

  • University of Michigan

    Ann Arbor, Michigan

  • University at Buffalo

    Buffalo, New York

  • Mecklenburg EMS

    Charlotte, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health and Sciences University

    Portland, Oregon

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • University of Texas Southwestern

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Washington

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.